Clinical trial
Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer
NCT00003786 · University of Chicago, Other · Withdrawn
Key facts
| NCT number | NCT00003786 |
|---|---|
| Title | Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer |
| Official title | A Phase II Trial of MGI-114 (NSC# 683863) Administered as a 5-Minute Infusion Daily for Five Days Every 4 Weeks in Patients With Previously Untreated Advanced Colorectal Cancer |
| Lead sponsor | University of Chicago, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | irofulven |
| Enrollment | 0 |
| Start date | Apr 1, 1999 |
| Primary completion | Nov 1, 2000 |
| Completion | Nov 1, 2000 |
| First posted | Aug 4, 2004 |
| Last update posted | Mar 7, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: